Hyperforin is a plant derived antibiotic from St. John's wort. Here we describe a novel activity of hyperforin, namely its ability to inhibit the growth of tumour cells by induction of apoptosis. Hyperforin inhibited the growth of various human and rat tumour cell lines in vivo, with IC 50 values between 3 ± 15 mM. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, typical DNA-laddering and apoptosis-speci®c morphological changes. In MT-450 mammary carcinoma cells hyperforin increased the activity of caspase-9 and caspase-3, and hyperforin-mediated apoptosis was blocked by the broad-range caspase inhibitor zVAD.fmk. When added to MT-450 cells, hyperforin, but not paclitaxel, induced a rapid loss of the mitochondrial transmembrane potential Dc m , and subsequent morphological changes such as homogenization and vacuolization of mitochondria. Monitoring of Dc m revealed that the hyperforin-mediated mitochondrial permeability transition can not be prevented by zVAD.fmk. This indicates that mitochondrial permeabilization is a cause rather than a consequence of caspase activation. Moreover, hyperforin was capable of releasing cytochrome c from isolated mitochondria. These ®ndings suggest that hyperforin activates a mitochondria-mediated apoptosis pathway. In vivo, hyperforin inhibited the growth of autologous MT-450 breast carcinoma in immunocompetent Wistar rats to a similar extent as the cytotoxic drug paclitaxel, without any signs of acute toxicity. Owing to the combination of signi®cant antitumour activity, low toxicity in vivo and natural abundance of the compound, hyperforin holds the promise of being an interesting novel antineoplastic agent that deserves further laboratory and in vivo exploration.
Introduction
An exciting aspect of apoptosis is that it can be utilized in the treatment of cancer (Revillard et al., 1998; Nicholson, 2000) . Anticancer agents with dierent modes of action have been reported to trigger apoptosis in chemosensitive cells (Hickman, 1992; Debatin, 1999) . The process of apoptosis consists of dierent phases, including initiation, execution and degradation (Kroemer, 1997) , and is activated by two major pathways. One of these is receptor-induced apoptosis which involves the TNF-family of death receptors, including the TNF-R1, CD95 (Fas) and TRAIL-receptors (Ashkenazi and Dixit, 1998; Martinez-Lorenzo et al., 1998) . In this so-called`extrinsic' cell death pathway, a cytoplasmic death domain forms upon ligand binding and trimerization of the receptor (Tartaglia et al., 1993) , and recruits adapter proteins like TRADD and FADD. This signalling complex activates an initiator caspase (caspase-8) that, upon accumulation, in turn activates further eector caspases (Thornberry and Lazebnik, 1998; Krammer, 2000; Liu et al., 1996) . The other major route leading to apoptosis is the`intrinsic' cell death pathway which is activated by the release of proapoptotic factors from mitochondria, including cytochrome c and Apaf-1 ( Thornberry and Lazebnik, 1998; Liu et al., 1996; Zamzami et al., 1995; Castedo et al., 1996; Reed, 1997; Green and Reed, 1998) . In the presence of ATP, these factors recruit procaspase-9 which is converted to caspase-9 and becomes part of the so-called apoptosome complex that activates the caspase cascade (Hengartner, 2000) . The release of cytochrome c from the mitochondria is regulated by members of the Bcl-2 protein family (Kroemer, 1997; Kluck et al., 1997; Wolter et al., 1997; Adams and Cory, 1998; Goping et al., 1998; Kroemer and Reed, 2000) . Overexpression of Bcl-2 prevents the eux of cytochrome c from the mitochondria and the initiation of apoptosis (Kroemer, 1997; Yang et al., 1997) . The release of mitochondrial factors is usually associated with a reduction in the mitochondrial transmembrane potential that can be measured by carbocyanide dyes such as DiOC 6 (3) (3,3'dihexyloxacarbocyanine iodide) (Zamzami et al., 1995; Castedo et al., 1996; Green and Reed, 1998; Kroemer and Reed, 2000) .
Cytotoxic drugs such as doxorubicin and paclitaxel initiate apoptosis of tumour cells via the Fas/Fas ligand system (Friesen et al., 1996; Srivastava et al., 1999) . On the other hand, the plant-derived anticancer drug betulinic acid selectively inhibits neuroectodermal tumours (Pisha et al., 1995) , and has been shown to induce apoptosis via the release of proapoptotic factors from mitochondria (Fulda et al., 1998) .
St. John's wort (Hypericum perforatum L.) is a member of the hypericaceae plant family. Recently, it has gained a reputation as an eective treatment for depression (Linde et al., 1996) . In traditional European medicine, lipophilic extracts of St. John's wort have been used for the topical treatment of burns and skin injuries (Roth, 1990) . One of the active ingredients of St. John's wort is the phloroglucin-derivative hyperforin (Bystrov et al., 1975; Erdelmeier, 1998) . Hyperforin is an acylphloroglucinol-type compound that consists of a phloroglucinol skeleton substituted with lipophilic isoprenchains ( Figure 1 ). It is a natural antibiotic that inhibits the growth of several gram-positive bacteria including meticillin resistant Staphylococcus aureus (Gurevich et al., 1971; Schempp et al., 1999) . Recent studies suggest hyperforin is an important neurotransmitter reuptake-inhibiting constituent of St. John's wort (MuÈ ller et al., 1998) . In a previous study we observed a dose-dependent antiproliferative eect of hyperforin in PHA-stimulated peripheral blood lymphocytes (Schempp et al., 2000) . Together with the previous report that hyperforin-related substances (hyperevolutins) inhibit the growth of a colon carcinoma cell line (Decosterd et al., 1989) , these ®ndings prompted us to adress the question of whether hyperforin displays antiproliferative eects on tumour cells. Hyperforin inhibited the growth of several tumour cell lines in a dose-dependent manner. Furthermore, we demonstrated in dierent readout systems that hyperforin exerts its inhibitory eects by activation of a mitochondria-mediated apoptosis pathway. Finally, in an animal model, we observed that hyperforin is able to inhibit the growth of tumour cells in vivo.
Results

Hyperforin inhibits tumour cell growth in vitro by induction of apoptosis
The antiproliferative potential of hyperforin was ®rst evaluated in six cancer cell lines by [ Additionally, 10 human and seven rat cell lines were screened for the cytotoxic eect of hyperforin in comparison to the antineoplastic drugs vincristine, paclitaxel and camptothecin. These drugs were tested at their usual eective in vitro concentrations, and cell proliferation was measured by BrdU incorporation. The results are summarized in Table 1 . Hyperforin was eective in all cell lines except BDX2 (IC 50 40 mg/ ml), whereas several of the cell lines were resistant to the other cytostatic drugs at the tested concentrations (Table 1) .
We next questioned whether the inhibition of tumour cells by hyperforin was associated with the induction of apoptosis. Apoptosis was determined in dierent readout systems. First, lysates of all above mentioned cell lines were evaluated for the content of apoptotic oligonucleosomes by a colorimetric ELISA. Figure 2B shows a dose-dependent increase of DNA fragmentation in all cell lines after treatment with hyperforin. Apoptosis was further con®rmed in Jurkat cells by DNA-gel electrophoresis and ultrastructural evaluation. DNA extracted from cells treated with hyperforin showed an increased generation of apoptotic DNA fragments as compared with solvent-treated control cells (Figure 3a) . The DNA ladder of the solvent control results from spontaneous apoptosis in Jurkat cells growing in culture that can also be observed in Figure 2b .
Electron microscopy revealed apoptosis-speci®c features of hyperforin-treated cells such as nuclear condensation, karyorhexis and cytoplasmic edema ( Figure 3b ). It is concluded that hyperforin is capable of inhibiting the proliferation of cancer cells by induction of apoptosis. Similar experiments also Figure 1 Chemical structure of hyperforin con®rmed that hyperforin induces apoptosis in MT450 cells (data not shown).
Hyperforin-induced apoptosis of tumour cells is associated with activation of caspases
To further elucidate the mechanisms of hyperforininduced apoptosis we assessed the possible involvement of caspases. MT-450 cells were incubated with 20 mM hyperforin and 10 mM paclitaxel for 12 h. The enzymatic activity of caspase-9 and caspase-3 was increased by treatment with hyperforin, whereas caspase-8 activity remained unchanged. In contrast, treatment with paclitaxel also resulted in a strong increase of caspase-8 activity ( Figure 4a ). Both hyperforin and paclitaxel-induced apoptosis could be blocked by the cell-permeable caspase inhibitor zVAD.fmk ( Figure  4b ), illustrating the functional relevance of caspase activation during drug-induced apoptosis. The absence of caspase-8 activation in the presence of caspase-9 activation during early hyperforin-induced apoptosis could be due to activation of the`intrinsic' cell death pathway, because caspase-9 is part of the mitochondria-related apoptosome complex (Hengartner, 2000) . We therefore asked whether hyperforin has a direct eect on mitochondria.
Mitochondrial activation is an early event during hyperforin-mediated apoptosis
MT-450 cells were incubated with hyperforin and paclitaxel and were stained with the carbocyanide dye The kinetics of Dc m was assessed in MCF-7 cells using a video microscope. MCF-7 cells (2710 5 /ml) were grown on sterile coverslips, washed and incubated for 10 min with hyperforin (20 mM) in the presence or absence of the caspase inhibitor zVAD.fmk (50 mM). Hyperforin causes release of cytochrome c from isolated mitochondria
To address the question of whether hyperforin induces cytochrome c release from mitochondria, a mitochondria-enriched fraction prepared from HEK-293 cells was incubated in the presence or absence of hyperforin (20 mM) or staurosporine (10 mM) for 0, 5, 10 and 30 min. We observed a rapid release of cytochrome c from hyperforin-treated mitochondria that was comparable to staurosporine ( Figure 6 ).
Hyperforin inhibits tumour growth in vivo
To assess the potential of hyperforin to inhibit tumour growth in vivo, female Wistar Furth rats were injected subcutaneously with rat mammary carcinoma MT-450 cells. Drug treatment with equimolar (2 mm) concentrations of hyperforin or paclitaxel was initiated 15 days after tumour injection, with daily s.c. injections over a period of two weeks. As shown in Figure 6 , hyperforin inhibited tumour growth to a similar extent as compared with paclitaxel. In each of the treatment groups, a complete lack of toxicity, as judged by changes in body weight or other forms of acute toxicity, was noted.
Discussion
Here we describe the potential of hyperforin to inhibit the growth of 17 human and rat tumour cell lines in vitro. Cytotoxic drugs act primarily by inducing apoptosis in sensitive target cells (Hickman, 1992; Debatin, 1999) . We therefore evaluated apoptosis of hyperforin-treated cells in dierent readout systems. Treatment of tumour cells with hyperforin resulted in a dose-dependent generation of apoptotic oligonucleosomes, increased DNA-laddering and apoptosis-speci®c morphological changes.
Our data suggest that hyperforin acts by triggering the`intrinsic' cell death pathway. Firstly, by using speci®c ELISAs, we found that treatment with hyperforin resulted in activation of caspase-9 and caspase-3. We tested a caspase inhibitor for its eect on cell death induced by hyperforin. Using MT-450 cells, the broad-range caspase inhibitor zVAD.fmk completely blocked apoptosis induced by hyperforin. This indicates that caspases downstream of mitochondria are important eectors of hyperforin-induced apoptosis. Secondly, when added to intact tumour cells, hyperforin but not paclitaxel speci®cally induced early mitochondrial alterations. These consisted of a loss of Dc m that could be detected as early as 30 min after treatment with hyperforin, and subsequent morphological changes such as homogenization and vacuolization of mitochondria, detected within 12 h after treatment with hyperforin.
We have also shown that the caspase inhibitor zVAD.fmk did not interfere with hyperforin-induced Dc m dissipation. Thus, hyperforin can directly trigger mitochondrial permeability transition without involvement of a zVAD.fmk-inhibitable caspase. Consistently, we observed a rapid release of cytochrome c from hyperforin-treated mitochondria. These data are in favour of the hypothesis that hyperforin is able to inhibit tumour cell growth by triggering the`intrinsic' cell death pathway. Although the early mitochondrial changes are consistent with this putative mechanism of action, we cannot rule out the possibility that hyperforin kills tumour cells by inducing some other damage to cells which then activates the apoptotic program. The precise molecular mechanisms of hyperforin-induced apoptosis are currently under investigation. A highly important ®nding from the studies presented here is that in addition to inducing tumour cell apoptosis in vivo, hyperforin also inhibited the growth of autologous MT-450 breast carcinoma cells in vivo in immunocompetent Wistar rats. Tumour growth was inhibited to a similar extent as with the cytotoxic drug paclitaxel, in the absence of any signs of acute toxicity. This observation is important, because paclitaxel is a drug which is already widely used as an anticancer agent in the clinical setting (Rowinsky and Donehower, 1995) . The dose of paclitaxel used in our experiment was about 10 times under the dose normally used in animal experiments. This was necessary because we wanted to use equimolar concentrations of paclitaxel and hyperforin, and we were not able to increase the concentration of the lipophilic compound hyperforin in an aqeous solution. However, we are improving the solubility of hyperforin at the present and hopefully we will soon be able to present further data on the mean tolerated dose and eectivity of hyperforin in vivo.
Although mammary carcinoma cells were the most sensitive to hyperforin in terms of inhibition of proliferation, hyperforin inhibited proliferation and induced apoptosis in all tumour cells tested. These . Cell lysates were tested for protease activity by the addition of caspase-speci®c peptides conjugated to the colour reporter p-nitroanilide. Compared with the untreated control, the enzymatic activity of caspase-9 and caspase-3 was increased by treatment with hyperforin, whereas caspase-8 activity remained unchanged. In contrast, treatment with paclitaxel also resulted in a strong increase of caspase-8 activity. (b) MT-450 cells were treated for 24 h with 20 mM hyperforin or 10 mM paclitaxel in the presence or absence of the caspase inhibitor zVAD.fmk (50 mM). Cells were then evaluated for apoptosis using a cell death detection ELISA. Data represent the means +s.d. of three experiments. **P50.01 (Students paired t-test) observations suggest that hyperforin might be a broadspectrum anti-tumour reagent, with activity against a wide range of dierent cancers.
Signi®cant antitumour activity in the absence of toxicity in vivo is a prerequisite for the development of new anticancer drugs. Another requirement for the development of new plant-derived anticancer drugs is ample supply in terms of plant availability and yield of the chemotherapeutic agent. Acylphloroglucinol-type compounds, of which hyperforin is the principal component, represent the largest group of compounds in St. John's wort (Hypericum perforatum). Crude extracts of the drug contain up to 5% of hyperforin (Roth, 1990; Erdelmeier, 1998; Maisenbacher and Kovar, 1992) . St. John's wort is found in abundance throughout Europe, North America, Asia and North Africa.
Together with low toxicity in vivo and natural abundance of the compound, we suggest that hyperforin is a potential antitumour drug that thoroughly deserves further investigation.
Materials and methods
Hyperforin and cytotoxic drugs
Hyperforin was extracted under protection from light and air from a supercritical CO 2 -extract of Hypericum perforatum (Flavex, Rehlingen, Germany). The CO 2 -extract was mixed with methanol (1 : 10, w : v), centrifuged and evaporated. The residue was chromatographed on a preparative silica gel plate (silica gel 60 F254, 20620 cm, 0.5 mm; mobile phase : hex- Hyperforin causes release of cytochrome c from isolated mitochondria. A mitochondria-enriched fraction was prepared from HEK-293 cells as described in the Materials and methods. The isolated mitochondria were resuspended in MSH buer supplemented with proteinase inhibitors and were incubated in the presence or absence of hyperforin (20 mM) or staurosporine (10 mM). Supernatants were collected after 0, 5, 10 and 30 min and their cytochrome c content was determined using a speci®c ELISA. The experiment was repeated with similar results ane:diethylether 80 : 20) (Merck, Darmstadt, Germany), and on a silica gel column (LiChrospher # Si 10, 12 mM; mobile phase: cyclohexane : ethylacetate gradient) (Merck, Darmstadt). The resulting extracts were combined, evaporated, dried an analysed. The hyperforin content of the dried residue was 490%. The identity of hyperforin was con®rmed by HPLC/PDA, 1 H-NMR-, 13 C-NMR-, IR-and and UVspectral analysis. The purity of hyperforin was assessed by two dierent validated HPLC-methods. All steps of the isolation were controlled by analytical HPLC. To obtain hyperforin aliquots, the compound was dissolved in methanol and known amounts of hyperforin were evaporated in brown glass tubes. The tubes were stoppered and were stored at 7308C under a liquid nitrogen atmosphere. Repeated analytical controls revealed a maximal decrease of hyperforin of 0.5% during a storage period of 6 months. Paclitaxel was obtained from Tocris (Tocris Cookson, MO, USA). Camptothecin, staurosporine and vincristine were obtained from Sigma (Sigma, St. Louis, MO, USA). All drugs were dissolved in DMSO and further diluted with phosphatebuered saline (PBS) to obtain stock solutions. Further dilutions were made with medium to obtain ®nal concentrations as indicated. The maximal ®nal DMSO concentration was 1%.
Cell lines
The following cell lines were used: A-431, human epidermoid carcinoma; HT-144, human melanoma; Jurkat, human acute T cell leukemia; MCF-7, human breast adenocarcinoma, expressing estrogen receptors; MDA-MB-468; human breast adenocarcinoma, lacking estrogen receptor expression; SK-OV-3, human ovary carcinoma, lacking p53 expression; HEK-293, human embryonal kidney cells (all from ATCC, Manassas, VA, USA); SB1 and SB3, human melanoma, were a gift from Dr CM Hamby (New York Medical College, Valhalla, NY, USA); MV3 and 1F6, human melanoma, were a gift from Dr GP van Muijen (Dept. of Pathology, Nijmegen, The Netherlands); MAT-Lu and AT-2.1, rat prostate carcinoma (Isaacs et al., 1986) ; AR42J and ARIP, rat pancreas carcinoma (ATCC); RG2, rat glioblastoma (ATCC); BDX2, rat ®brosarcoma (Sleeman et al., 1996) ; and MT-450, rat breast adenocarcinoma (Kim, 1986; Sleeman et al., 1999) .
All cells, with the exception of MCF-7, were cultured in RPMI supplemented with 10% FCS, 1% L-Glutamine and 1% Penicillin/Streptomycin (all from Gibco, Eggenstein, Germany) in a humidi®ed athmosphere (5% CO 2 , 378C). MCF-7 cells were grown in Dulbeccos minimal essential medium supplemented with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1.0 mM sodium pyruvate, 10% FBS, 1% L-glutamine and 1% Penicillin/Streptomycin (Gibco). (Schempp et al., 2000) . Data are expressed as per cent of control (mean of three independent experiments). Alternatively, the incorporation of 5-bromo-2'-deoxyuridine (BrdU) into the DNA of proliferating cells was measured using a colorimetric BrdU cell proliferation ELISA (Roche Molecular Biochemicals, Mannheim, Germany). The assay was performed according to the manufacturer's instructions.
Photometric determination of apoptosis
Cells (1610 4 cells/ml) were treated with various hyperforin concentrations for 24 h as described above. Cells were then evaluated for apoptosis using a cell death detection ELISA (Cell Death Detection ELISA PLUS , Roche Molecular Biochemicals). The principle of this test is the detection of monoand oligonucleosomes in the cytoplasmic fractions of cell lysates using biotinylated anti-histone and peroxidase-coupled anti-DNA antibodies. The amount of nucleosomes is photometrically quanti®ed at 405 nm by the peroxidase activity retained in the immunocomplexes. Data are expressed as mean of three independent experiments. In a separate experiment, MT-450 cells (1610 4 cells/ml) were treated for 24 h with 20 mM hyperforin or 10 mM paclitaxel in the presence or absence of the caspase inhibitor zVAD.fmk (50 mM) (R&D Systems, Wiesbaden, Germany) and apoptosis was determined as described above.
DNA gel electrophoresis
Apoptotic DNA fragments were isolated from Jurkat cells treated for 12 h with hyperforin (20 mM) as described (Herrmann et al., 1994; Schempp et al., 2001) . Brie¯y, cells were washed and pelleted by centrifugation. Cell pellets were treated for 10 s with lysis buer (1% NP40; 20 mM EDTA; 50 mM Tris-HCl, all from Sigma). The cells were then mixed with 1% SDS (Sigma), treated for 2 h with RNase (5 mg/ml) (Boehringer, Mannheim, Germany) at 568C and digested with proteinase K (2.5 mg/ml) (Sigma) for 2 h at 378C. After addition of 10 m ammonium acetate (Merck, Darmstadt, Germany) the DNA was precipitated with 100% ethanol at 5 MT-450 cells in PBS. Drug treatment was initiated 15 days after tumour cell injection when tumours were readily detectable and easily measured. The animals received 100 ml of 2 mm hyperforin (n=8), 2 mM paclitaxel (n=8), or solvent (n=8). Daily injections were administered subcutaneously at the site of the tumour cell injection for two weeks. Data are indicated as mean + standard error of mean 7208C, resuspended in gel loading buer (10 mM Tris-HCl, 1 mM EDTA, Sigma) and separated on 3% agarose gels together with a KiloBase TM DNA marker (Pharmacia, Freiburg, Germany).
Electron microscopy
Jurkat cells (1610 6 /ml) were treated with 20 mM hyperforin for 24 h, and MT-450 cells were treated with 20 mM hyperforin for 30 min, 12 h and 24 h, respectively. After centrifugation, cell pellets were ®xed for 12 h in 3% cacodylate-buered glutaraldehyde. Ultrathin sections (50 nm) were stained with 5% uranyl acetate and 0.2% lead citrate. Examination was carried out using a Philips CM10 electron microscope (Philips, Eindhoven, The Netherlands).
Caspase assay
To determine the enzymatic activity of caspases-3, -8 and -9, semi-quantitative colorimetric ELISA's were performed. MT-450 cells (1610 5 /ml) were treated for 12 h with 20 mM Hyperforin or 10 mM Paclitaxel. Cells were lysed in ice-cold hypotonic buer containing 20 mM Tris-HCl (pH 7.2), 1 mM EDTA and protease inhibitors to prevent nonspeci®c cleavage of proteins. Homogenates were clari®ed by centrifugation for 10 min at 16 0006g. Cell lysates were then tested for protease activity by the addition of caspase-speci®c peptides conjugated to the colour reporter p-nitroanilide (R&D systems). The cleavage of the peptide by the caspase releases the chromophore, which is quantitated spectrophotometrically at 405 nm. The level of caspase enzymatic activity is directly proportional to the colour reaction.
Determination of the mitochondrial membrane potential Dc m MT-450 cells (1610 6 /ml) were treated for 20 min with 20 mM Hyperforin or 10 mM Paclitaxel. The cells were then incubated for 10 min with DiOC 6 (3) (50 nm; Molecular Probes, Eugene, OR, USA) at 378C, washed in PBS and analysed on a FACScan¯ow cytometer (Becton Dickinson, San Jose, CA, USA) and by¯uorescence microscopy (Zeiss, Jena, Germany). The kinetics of Dc m were assessed in MCF-7 cells using timelapse video microscopy as described previously (TILL Photonics, Martinsried, Germany) . MCF-7 cells (2610 5 /ml) were grown on sterile coverslips for 12 h. The cells were washed and were incubated for 10 min with hyperforin (20 mM) in the presence or absence of the caspase inhibitor zVAD.fmk (50 mM). Subsequently, the coverslips were rinsed with PBS and were transferred into the closed bath¯ow micro-chamber (378C) of the video microscope. DiOC 6 (3) (50 nM ®nal concentration) was injected directly into the chamber and microphotographs were taken every 5 s over a period of 60 min. The mean¯uorescence (584 nm) of 30 randomly selected cells per ®lm were calculated with the TILL Vision TM v3.3 software.
Cytochrome c release from isolated mitochondria 5610 7 HEK-293 cells were harvested, washed in PBS and resuspended in MSH buer (210 mM mannitol, 70 mM sucrose, 20 mM HEPES, 1 mM EDTA, pH 7.4) plus protease inhibitors. The cells were lysed by passing them ®ve times through a 21G and a 23G needle. Nuclei and cellular debris were removed by centrifugation at 5006g for 5 min. The post-nuclear supernatant was centrifuged at 51006g for 10 min, and the obtained pellet was washed twice in PBS. The resulting crude mitochondria were resuspended in MSH buer and stored at 48C until use. Mitochondria were treated with hyperforin (20 mM) or staurosporine (10 mM), and mitochondrial supernatants were obtained by high speed centrifugation (15 0006g, 5 min, 48C) after 0, 5, 10 and 30 min. The cytochrome c content of the supernatants was measured using a speci®c ELISA (R&D systems).
Tumour growth in vivo
Female Wistar Furth rats were injected subcutaneously with 5610 5 MT-450 cells in PBS. Drug treatment was initiated 15 days after tumour injection, a time at which tumours were readily detectable and could easily be measured. The animals received 100 ml of 2 mM drug solution (hyperforin, eight per group; paclitaxel, eight per group) or the solvent (10% DMSO, eight per group). Daily injections of the drugs/ control were administered subcutaneously at the site of the tumour cell injection for two weeks. Tumours were measured with a micrometre calliper every third day throughout the study (Sleeman et al., 1999) . Studies with laboratory animals were approved by the local Ethical Review Board.
Statistical analysis
The mean and standard deviation of several experiments is shown, unless otherwise indicated. The number of experiments and the con®rmatory tests used are indicated in the ®gure legends.
